Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non-small-cell Lung Cancer Exhibiting Resistance to Ceritinib

被引：52
|
作者：
Toyokawa, Gouji [1 ]
Inamasu, Eiko [1 ]
Shimamatsu, Shinichiro [1 ]
Yoshida, Tsukihisa [1 ]
Nosaki, Kaname [1 ]
Hirai, Fumihiko [1 ]
Yamaguchi, Masafumi [1 ]
Seto, Takashi [1 ]
Takenoyama, Mitsuhiro [1 ]
Ichinose, Yukito [1 ]
机构：
[1] Kyushu Natl Canc Ctr, Dept Thorac Oncol, Minami Ku, Fukuoka 8111395, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 07期
基金：
日本学术振兴会;
关键词：
NSCLC PATIENTS; ALECTINIB; CRIZOTINIB;
D O I：
10.1097/JTO.0000000000000509
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：E55 / E57
页数：3
相关论文
共 50 条
  • [1] Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
    Shaw, Alice T.
    Kim, Dong-Wan
    Mehra, Ranee
    Tan, Daniel S. W.
    Felip, Enriqueta
    Chow, Laura Q. M.
    Camidge, D. Ross
    Vansteenkiste, Johan
    Sharma, Sunil
    De Pas, Tommaso
    Riely, Gregory J.
    Solomon, Benjamin J.
    Wolf, Juergen
    Thomas, Michael
    Schuler, Martin
    Liu, Geoffrey
    Santoro, Armando
    Lau, Yvonne Y.
    Goldwasser, Meredith
    Boral, Anthony L.
    Engelman, Jeffrey A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (13): : 1189 - 1197
  • [2] Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
    Shen, Liang
    Ji, Hong-Fang
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (26): : 2537 - 2537
  • [3] Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond
    Kanaan, Zeyad
    Kloecker, Goetz H.
    Paintal, Ajit
    Perez, Cesar A.
    ONCOTARGETS AND THERAPY, 2015, 8 : 885 - 892
  • [4] Crizotinib primary resistance overcome by ceritinib in a patient with ALK-rearranged non-small cell lung cancer
    Facchinetti, Francesco
    Caramella, Caroline
    Auger, Nathalie
    Planchard, David
    Adam, Julien
    Lacroix, Ludovic
    Remon, Jordi
    Massard, Christophe
    Soria, Jean-Charles
    Friboulet, Luc
    Besse, Benjamin
    TUMORI JOURNAL, 2016, 102 : S46 - S49
  • [5] Molecular imaging as a predictive biomarker response to Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
    Medina-Ornelas, S.
    Garcia-Perez, F.
    Arrieta-Rodriguez, O.
    Barron-Barron, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S568 - S568
  • [6] Targeting ALK-rearranged non-small-cell lung cancer: an update
    Sullivan, Ivana
    Planchard, David
    FUTURE ONCOLOGY, 2017, 13 (14) : 1213 - 1217
  • [7] Ceritinib (LDK378): A Potent Alternative to Crizotinib for ALK-Rearranged Non-Small-Cell Lung Cancer
    Li, Sen
    Qi, Xiaolong
    Huang, Yufeng
    Liu, Dingfeng
    Zhou, Fangyu
    Zhou, Caicun
    CLINICAL LUNG CANCER, 2015, 16 (02) : 86 - 91
  • [8] Ceritinib-a second-generation ALK inhibitor overcoming resistance in ALK-rearranged non-small cell lung cancer
    Rothschild, Sacha I.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (06) : 379 - 381
  • [9] Identification of a novel resistance ALK p.(Q1188_L1190del) deletion in a patient with ALK-rearranged non-small-cell lung cancer
    Suryavanshi, Moushumi
    Chaudhari, Krushna
    Nathany, Shrinidhi
    Talwar, Vineet
    CANCER GENETICS, 2021, 256 : 48 - 50
  • [10] Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer
    Sullivan, Ivana
    Planchard, David
    FUTURE ONCOLOGY, 2016, 12 (07) : 945 - 961
12345